Literature DB >> 19563377

Review article: Early detection of chronic kidney disease in Australia: which way to go?

Timothy Mathew1, Olivia Corso.   

Abstract

Early detection of chronic kidney disease (CKD) followed by appropriate clinical management appears the only means by which the increasing burden on the health-care system and affected individuals will be reduced. The asymptomatic nature of CKD means that early detection can only occur through testing of individuals. The World Health Organization principles of screening for chronic disease can now be largely fulfilled for CKD. The risk groups to be targeted, the expected yield and the tests to be performed are reviewed. For a screening programme to be sustainable it must carry a greater benefit than risk of harm for the participant and be shown to be cost-effective from the community point of view. Whole population screening for CKD is impractical and is not cost-effective. Screening of those at increased risk of CKD could occur either through special events run in the community, workplace or in selected locations such as pharmacies or through opportunistic screening of high-risk people in general practice. Community screening programmes targeted at known diabetics, hypertensives and those over 55 years have been described to detect 93% of all CKD in the community. The yield of CKD stages 3-5 from community screening has been found to vary from 10% to 20%. The limitations of screening programmes including the cost and recruitment bias are discussed. The most sustainable and likely the most cost-efficient model appears to be opportunistic general practice screening. The changing structure of general practice in Australia lends itself well to the requirements for early detection of CKD.

Entities:  

Mesh:

Year:  2009        PMID: 19563377     DOI: 10.1111/j.1440-1797.2009.01113.x

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  11 in total

1.  Trends in estimated kidney function: the FINRISK surveys.

Authors:  Auni Juutilainen; Helena Kastarinen; Riitta Antikainen; Markku Peltonen; Veikko Salomaa; Jaakko Tuomilehto; Pekka Jousilahti; Jouko Sundvall; Tiina Laatikainen; Mika Kastarinen
Journal:  Eur J Epidemiol       Date:  2012-04       Impact factor: 8.082

Review 2.  Effectiveness of targeted screening for chronic kidney disease in the community setting: a systematic review.

Authors:  Pankti A Gheewala; Syed Tabish R Zaidi; Matthew D Jose; Luke Bereznicki; Gregory M Peterson; Ronald L Castelino
Journal:  J Nephrol       Date:  2017-02-08       Impact factor: 3.902

3.  A web-based training program to support chronic kidney disease screening by community pharmacists.

Authors:  Pankti A Gheewala; Gregory M Peterson; Syed Tabish R Zaidi; Luke Bereznicki; Matthew D Jose; Ronald L Castelino
Journal:  Int J Clin Pharm       Date:  2016-06-21

4.  Mastering a mediator: blockade of CCN-2 shows early promise in human diabetic kidney disease.

Authors:  Stephen M Twigg
Journal:  J Cell Commun Signal       Date:  2010-10-19       Impact factor: 5.782

5.  Patient satisfaction with a chronic kidney disease risk assessment service in community pharmacies.

Authors:  Pankti A Gheewala; Gregory M Peterson; Syed Tabish R Zaidi; Matthew D Jose; Ronald L Castelino
Journal:  Int J Clin Pharm       Date:  2018-02-13

6.  In memorandum of world kidney day: chronic kidney disease: a common but often unnoticed major health problem.

Authors:  M K Fallahzadeh; M M Sagheb; M H Fallahzadeh
Journal:  Iran Red Crescent Med J       Date:  2011-03-01       Impact factor: 0.611

7.  Clinical outcomes associated with albuminuria in central Australia: a cohort study.

Authors:  Rebecca Ritte; Joanne Luke; Craig Nelson; Alex Brown; Kerin O'Dea; Alicia Jenkins; James D Best; Robyn McDermott; Mark Daniel; Kevin Rowley
Journal:  BMC Nephrol       Date:  2016-08-05       Impact factor: 2.388

Review 8.  Chronic kidney disease in low-income to middle-income countries: the case for increased screening.

Authors:  Cindy George; Amelie Mogueo; Ikechi Okpechi; Justin B Echouffo-Tcheugui; Andre Pascal Kengne
Journal:  BMJ Glob Health       Date:  2017-05-29

9.  Public knowledge of chronic kidney disease evaluated using a validated questionnaire: a cross-sectional study.

Authors:  Pankti A Gheewala; Gregory M Peterson; Syed Tabish R Zaidi; Matthew D Jose; Ronald L Castelino
Journal:  BMC Public Health       Date:  2018-03-20       Impact factor: 3.295

10.  Australian Community Pharmacists' Experience of Implementing a Chronic Kidney Disease Risk Assessment Service.

Authors:  Pankti A Gheewala; Gregory M Peterson; Syed Tabish R Zaidi; Matthew D Jose; Ronald L Castelino
Journal:  Prev Chronic Dis       Date:  2018-06-14       Impact factor: 2.830

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.